Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years

Published:November 19, 2021DOI:


      • Long terms outcomes after reirradiation for prostate cancer.
      • Promising biochemical control of disease after this approach.
      • Low rate of reported adverse events after treatment.
      • Gleason <7 significantly influencing clinical outcomes after treatment.



      In 2018, we published early results from a cohort of patients treated with stereotactic body radiotherapy (SBRT) after previous radiotherapy with definitive or postoperative intent. We sought to provide extended follow-up of this cohort to confirm the safety and efficacy of this approach in a real-world scenario.

      Materials and methods

      Fifty patients affected by local relapse after previous definitive or postoperative radiotherapy were treated with SBRT. Treatment provided a total dose of 30 Gy in five fractions. Data about biochemical relapse-free survival (BRFS) and metastasis-free survival (MFS), together with adverse events, were analysed. Toxicity was reported according to Common Terminology Criteria for Adverse Events (CTCAE) score v.4.03.


      After a median follow-up of 48.2 months, the median BRFS was 43 months. A Gleason score >7 and concomitant androgen deprivation therapy were shown to be predictors of the worst BRFS (hazard ratio 2.42, 95% confidence interval 1.09–5.41, P = 0.02; hazard ratio 2.83, 95% confidence interval 1.17–6.8, P = 0.02, respectively). The median MFS was not reached; concomitant androgen deprivation therapy was confirmed to be predictive of the worst MFS (hazard ratio 4.75, 95% confidence interval 1.52–14.8, P = 0.007). Late grade 1 and 2 rectal and bladder toxicity occurred in three (6%) and 13 (26%) patients, respectively. One patient experienced both grade 3 acute and chronic bladder toxicity.


      Salvage SBRT re-irradiation after previous postoperative or definitive radiotherapy for local prostate cancer recurrence confirmed promising results in terms of oncological outcomes and the safety of this approach.

      Key words

      To read this article in full you will need to make a payment


      Subscribe to Clinical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Agarwal P.K.
        • Sadetsky N.
        • Konety B.R.
        • Resnick M.I.
        • Carroll P.R.
        Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care and outcomes.
        Cancer. 2008; 112: 307-314
        • Connolly J.A.
        • Shinohara K.
        • Presti J.C.
        • Carrol P.R.
        Local recurrence after radical prostatectomy: characteristics in size, location and relationship to prostate-specific antigen and surgical margins.
        Urology. 1996; 47: 225-231
        • Saleem M.D.
        • Sanders H.
        • Abu El Naser M.
        • El-Galley R.
        Factors predicting cancer detection in biopsy of the prostate fossa after radical prostatectomy.
        Urology. 1998; 51: 283-286
        • Ingrosso G.
        • Becherini C.
        • Lancia A.
        • Caini S.
        • Ost P.
        • Francolini G.
        • et al.
        Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis.
        Eur Urol Oncol. 2020; 3: 183-197
        • Tran H.
        • Kwok J.
        • Pickles T.
        • Tyldesley S.
        • Black P.C.
        Underutilization of local salvage therapy after radiation therapy for prostate cancer.
        Urol Oncol. 2014; 32: 701-706
        • Valle L.F.
        • Lehrer E.J.
        • Markovic D.
        • Elashoff D.
        • Levin-Epstein R.
        • Karnes R.J.
        • et al.
        A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER).
        Eur Urol. 2021; 80: 280-292
        • Bergamin S.
        • Eade T.
        • Kneebone A.
        • Booth J.
        • Hsiao E.
        • Schembri G.P.
        • et al.
        Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer.
        Int J Radiat Oncol Biol Phys. 2020; 108: 1172-1178
        • Loi M.
        • Di Cataldo V.
        • Simontacchi G.
        • Detti B.
        • Bonomo P.
        • Masi L.
        • et al.
        Robotic stereotactic retreatment for biochemical control in previously irradiated patients affected by recurrent prostate cancer.
        Clin Oncol. 2018; 30: 93-100
        • Jereczek-Fossa B.A.
        • Rojas D.P.
        • Zerini D.
        • Fodor C.
        • Viola A.
        • Fanetti G.
        • et al.
        Reirradiation for isolated local recurrence of prostate cancer: mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
        Br J Radiol. 2019; 92: 20180494
        • Fuller D.B.
        • Wurzer J.
        • Shirazi R.
        • Bridge S.S.
        • Law J.
        • Mardirossian G.
        High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
        Pract Radiat Oncol. 2015; 5: e615-e623
        • Janoray G.
        • Reynaud-Bougnoux A.
        • Ruffier-Loubière A.
        • Bernadou G.
        • Pointreau Y.
        • Calais G.
        Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: initial report.
        Cancer Radiother. 2016; 20: 275-281
        • Leroy T.
        • Lacornerie T.
        • Bogart E.
        • Nickers P.
        • Lartigau E.
        • Pasquier D.
        Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center.
        Radiat Oncol. 2017; 12: 95
        • Miszczyk L.
        • Stąpór-Fudzińska M.
        • Miszczyk M.
        • Maciejewski B.
        • Tukiendorf A.
        Salvage Cyberknife-based reirradiation of patients with recurrent prostate cancer: the single-center experience.
        Technol Cancer Res Treat. 2018; 17 (1533033818785496)
        • D'Agostino G.R.
        • Di Brina L.
        • Mancosu P.
        • Franzese C.
        • Iftode C.
        • Franceschini D.
        • et al.
        Reirradiation of locally recurrent prostate cancer with volumetric modulated arc therapy.
        Int J Radiat Oncol Biol Phys. 2019; 104: 614-621
        • Olivier J.
        • Basson L.
        • Puech P.
        • Lacornerie T.
        • Villers A.
        • Wallet J.
        • et al.
        Stereotactic re-irradiation for local recurrence in the prostatic bed after prostatectomy: preliminary results.
        Front Oncol. 2019; 9: 71
        • Cornford P.
        • Bellmunt J.
        • Bolla M.
        • Briers E.
        • De Santis M.
        • Gross T.
        • et al.
        EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer.
        Eur Urol. 2017; 71: 630-642
        • National Cancer Institute, National Institutes of Health
        Common terminology criteria for adverse events v4.0.
        NIH Publ, 2009 (0–71)
        • Benedict S.H.
        • Yenice K.M.
        • Followill D.
        • Galvin J.M.
        • Hinson W.
        • Kavanagh B.
        • et al.
        Stereotactic body radiation therapy: the report of AAPM Task Group 101.
        Med Phys. 2010; 37: 4078-4101
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • Schultz D.
        • Blank K.
        • Broderick G.A.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • Roach 3rd, M.
        • Marquez C.
        • Yuo H.S.
        • Narayan P.
        • Coleman L.
        • Nseyo U.O.
        • et al.
        Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 1994; 28: 33-37
        • Scher H.I.
        • Halabi S.
        • Tannock I.
        • Morris M.
        • Sternberg C.
        • Carducci M.
        • et al.
        Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
        J Clin Oncol. 2008; 26: 1148-1159
        • Francolini G.
        • Jereczek-Fossa B.A.
        • Di Cataldo V.
        • Simontacchi G.
        • Marvaso G.
        • Zerella M.A.
        • et al.
        Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series.
        BJU Int. 2020; 125: 417-425
        • Phillips R.
        • Shi W.Y.
        • Deek M.
        • Radwan N.
        • Lim S.J.
        • Antonarakis E.S.
        • et al.
        Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.
        JAMA Oncol. 2020; 6: 650-659
        • Jereczek-Fossa B.A.
        • Marvaso G.
        • Zaffaroni M.
        • Gugliandolo S.G.
        • Zerini D.
        • Corso F.
        • et al.
        on behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus.
        Cancer Treat Rev. 2021; 98: 102206
        • Feng F.Y.
        • Huang H.C.
        • Spratt D.E.
        • Zhao S.G.
        • Sandler H.M.
        • Simko J.P.
        • et al.
        Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial.
        JAMA Oncol. 2021; 7: 544-552
        • Hussain M.
        • Fizazi K.
        • Saad F.
        • Rathenborg P.
        • Shore N.
        • Ferreira U.
        • et al.
        Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.
        N Engl J Med. 2018; 378: 2465-2474
        • Smith M.R.
        • Saad F.
        • Chowdhury S.
        • Oudard S.
        • Hadaschik B.A.
        • Graff J.N.
        • et al.
        Apalutamide treatment and metastasis-free survival in prostate cancer.
        N Engl J Med. 2018; 378: 1408-1418
        • Fizazi K.
        • Shore N.
        • Tammela T.L.
        • Ulys A.
        • Vjaters E.
        • Polyakov S.
        • et al.
        Darolutamide in nonmetastatic, castration-resistant prostate cancer.
        N Engl J Med. 2019; 380: 1235-1246